Search results

532 results

Sorted by Relevance . Sort by Date

  1. Safe staffing for nursing in adult inpatient wards in acute hospitals (SG1)

    This guideline covers organisational and managerial approaches to safe nurse staffing of inpatient wards for people aged 18 and over in acute hospitals. It aims to ensure that patients receive the nursing care they need, regardless of the ward to which they are allocated, the time of the day, or the day of the week.

  2. Safe midwifery staffing for maternity settings (NG4)

    This guideline covers safe midwifery staffing in all maternity settings, including at home, in the community, in day assessment units, in obstetric units, and in units led by midwives (both alongside hospitals and free-standing). It aims to improve maternity care by giving advice on monitoring staffing levels and actions to take if there are not enough midwives to meet the needs of women and babies in the service.

  3. Inotersen for treating hereditary transthyretin amyloidosis (HST9)

    Evidence-based recommendations on inotersen (Tegsedi) for stage 1 and stage 2 polyneuropathy in adults with hereditary transthyretin amyloidosis

  4. Burosumab for treating X-linked hypophosphataemia in children and young people (HST8)

    Evidence-based recommendations on burosumab (Crysvita) for treating X-linked hypophosphataemia (XLH) in children and young people

  5. Asfotase alfa for treating paediatric-onset hypophosphatasia (HST6)

    Evidence-based recommendations on asfotase alfa (Strensiq) for treating paediatric-onset hypophosphatasia in adults and children

  6. Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (HST12)

    Evidence-based recommendations on cerliponase alfa (Brineura) for treating neuronal ceroid lipofuscinosis type 2 in children

  7. Voretigene neparvovec for treating inherited retinal dystrophies caused by RPE65 gene mutations (HST11)

    Evidence-based recommendations on voretigene neparvovec (Luxturna) for RPE65-mediated inherited retinal dystrophies in people with vision loss caused by inherit

  8. Patisiran for treating hereditary transthyretin amyloidosis (HST10)

    Evidence-based recommendations on patisiran (Onpattro) for treating hereditary transthyretin amyloidosis in adults with stage 1 and stage 2 polyneuropathy

  9. Eculizumab for treating atypical haemolytic uraemic syndrome (HST1)

    Evidence-based recommendations on eculizumab (Soliris) for treating atypical haemolytic uraemic syndrome in adults and children

  10. Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene (HST3)

    Evidence-based recommendations on ataluren (Translarna) for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene in people aged

  11. Endoscopic thoracic sympathectomy for primary facial blushing (IPG480)

    Evidence-based recommendations on endoscopic thoracic sympathectomy (cutting off nerve signals to stop blushing) for primary facial blushing

  12. Optical coherence tomography to guide percutaneous coronary intervention (IPG481)

    Evidence-based recommendations on optical coherence tomography to guide percutaneous coronary intervention (near-infrared light for artery imaging)

  13. Transoral carbon dioxide laser surgery for primary treatment of oropharyngeal malignancy (IPG484)

    Evidence-based recommendations on transoral carbon dioxide (CO2) laser surgery for primary treatment of oropharyngeal malignancy (throat cancer)

  14. Faecal microbiota transplant for recurrent Clostridium difficile infection (IPG485)

    Evidence-based recommendations on faecal microbiota (bacteria) transplant for recurrent Clostridium difficile (C. difficile/C. diff) infection

  15. Insertion of customised exposed titanium implants, without soft tissue cover, for complex orofacial reconstruction (IPG457)

    Evidence-based recommendations on inserting customised exposed titanium implants, (without soft tissue cover) for complex orofacial (face) reconstruction

  16. Endoscopic radiofrequency ablation for gastro-oesophageal reflux disease (IPG461)

    Evidence-based recommendations on endoscopic radiofrequency ablation for gastro-oesophageal reflux disease (acid reflux/ GORD/GERD)

  17. Insertion and use of implantable pulmonary artery pressure monitors in chronic heart failure (IPG463)

    Evidence-based recommendations on the insertion and use of implantation pulmonary artery pressure monitors for chronic heart failure

  18. Endoscopic thoracic sympathectomy for primary hyperhidrosis of the upper limb (IPG487)

    Evidence-based recommendations on endoscopic thoracic sympathectomy for primary hyperhidrosis (excess sweating) of the upper limb (palm of hand and armpit)

  19. Chemosaturation via percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic liver cancer (IPG488)

    Evidence-based recommendations on chemosaturation via percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic liver cancer

  20. Insertion of prostatic urethral lift implants to treat lower urinary tract symptoms secondary to benign prostatic hyperplasia (IPG475)

    Evidence-based recommendations on prostatic urethral lift implants to treat lower tract symptoms secondary to benign prostate hyperplasia (enlarged prostate)

  21. Electrochemotherapy for primary basal cell carcinoma and primary squamous cell carcinoma (IPG478)

    Evidence-based recommendations on electrochemotherapy for primary basal cell carcinoma (BCC) and primary squamous cell carcinoma (SCC) (skin cancer)

  22. Percutaneous closure of patent foramen ovale to prevent recurrent cerebral embolic events (IPG472)

    Evidence-based recommendations on percutaneous closure of patent foramen ovale (PFO/hole in the heart) to prevent recurrent cerebral embolic events

  23. Arthroscopic radiofrequency chondroplasty for discrete chondral defects of the knee (IPG493)

    Evidence-based recommendations on arthroscopic radiofrequency chondroplasty for discrete chondral defects of the articular cartilage in the knee